2023 – Page 1894 – 1stOncology™: Cancer Intelligence Service

First-in-class small molecule antifibrotic and anticancer agents

On January 6, 2023 Galecto Biotech presented its corporate presentation (Presentation, Galecto Biotech, JAN 6, 2023, View Source [SID1234625963]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

EVERSANA to Present at the 41st Annual J.P. Morgan Healthcare Conference

On January 6, 2023 Jim Lang, Chief Executive Officer of EVERSANA, reported that pioneer of next-generation commercial services to the global life sciences industry, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California (Press release, EVERSANA, JAN 6, 2023, View Source [SID1234625962]).

Lang, along with Chief Financial Officer Kelly Baker and Chief Digital Officer Scott Snyder, will be among EVERSANA leaders connecting with analysts and sharing market insights behind the company’s rapid evolution, from just over 1,000 employees in 2018 to more than 7,000 employees across 16 countries in 2022.

Since its launch in 2018, EVERSANA has built the industry’s first fully integrated commercialization solution, serving more than 650 partners ranging from established pharmaceutical companies to emerging start-ups. EVERSANA’s global commercial services are recognized for improving the launch and long-term in-market success for products across more than 50 therapeutic indications, including oncology, as well as advanced digital therapeutics.

"This conference is widely recognized as the global intersection of investment and innovation," said Lang. "We’re honored to get a chance to tell our story. But more so, we are humbled to share how our pharmaceutical clients are partnering with us as we transform an industry through digital innovation, award-winning client service, and an unwavering commitment to patients."

Lang will present on Monday, January 9, 2023, at 5:00 p.m. PST. Interested media or investors who wish to schedule a meeting with EVERSANA leadership can contact [email protected].

bluebird bio Sells Second Priority Review Voucher for $95 Million

On January 6, 2023 bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") reported that it has entered into a definitive agreement to sell its second Rare Pediatric Disease Priority Review Voucher (PRV) for $95 million (Press release, bluebird bio, JAN 6, 2023, View Source [SID1234625960]).

bluebird bio was granted two PRVs upon the US Food and Drug Administration (FDA) approvals of ZYNTEGLO (betibeglogene autotemcel) for the treatment of beta-thalassemia in adult and pediatric patients requiring regular red blood cell transfusions and SKYSONA (elivaldogene autotemcel) for the treatment of early, active cerebral adrenoleukodystrophy, on August 17, 2022 and September 16, 2022 respectively. On December 29, 2022, bluebird closed the sale of its first PRV for $102 million.

"The sale of our second priority review voucher further bolsters our financial position and provides an important source of non-dilutive funding for the company," said Chris Krawtschuk, chief financial officer, bluebird bio. "Strengthening the company’s balance sheet – as we have continued to do through demonstrated fiscal discipline and the sale of both PRVs – ensures we enter 2023 with significant momentum behind the commercial launches of our two FDA-approved gene therapies, and the opportunity ahead in sickle cell disease."

bluebird received a payment of $95 million upon closing of the transaction, which occurred simultaneously with the parties entering into the agreement. Jefferies LLC acted as the exclusive financial advisor to bluebird for this transaction.

About the Rare Pediatric Disease Priority Review Voucher Program

The Rare Pediatric Disease Priority Review Voucher Program is intended to encourage development of new drug and biological products for the prevention and treatment of certain rare pediatric diseases. Under this program, upon approval, the US Food and Drug Administration awards priority review vouchers to sponsors of rare pediatric disease product applications that meet certain criteria. The voucher can be redeemed to receive priority review of a subsequent marketing application for a different product. PRVs may be sold or transferred, and there is no limit on the number of times a PRV can be transferred.

AVEO Oncology Stockholders Approve Acquisition by LG Chem

On January 6, 2023 AVEO Oncology ("AVEO") (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, reported that at a special meeting of stockholders (the "Special Meeting") held today, AVEO stockholders approved the adoption of the Agreement and Plan of Merger among LG Chem, Ltd. ("LG Chem"), a subsidiary of LG Chem and AVEO (the "merger agreement") (Press release, AVEO, JAN 6, 2023, View Source [SID1234625959]). As previously announced, under the terms of the merger agreement, AVEO stockholders will receive $15.00 per share in cash upon the closing of the transaction.

"Today’s approval is a significant step toward the completion of AVEO’s transaction with LG Chem, and I thank our stockholders for their strong support," said Michael Bailey, President and Chief Executive Officer of AVEO. "As the U.S. late stage development and commercial foundation for LG Chem Life Sciences’ oncology segment, we believe AVEO will be well positioned to advance its mission of passionately pursuing a better life for patients with cancer."

The final voting results will be reported in a Current Report on Form 8-K to be filed by AVEO with the Securities and Exchange Commission after certification by AVEO’s inspector of elections. The stockholders also approved a non-binding, advisory proposal relating to certain compensation that may be paid or become payable to certain of AVEO’s executive officers that is based on or otherwise relates to the merger between AVEO and LG Chem.

Completion of the transaction remains subject to certain customary closing conditions, including clearance of the transaction by the Committee on Foreign Investment in the United States, and the transaction is expected to close in early 2023.

Advisors

BofA Securities is serving as exclusive financial advisor to LG Chem, and Latham & Watkins LLP is serving as LG Chem’s legal counsel. Moelis & Company LLC is serving as exclusive financial advisor to AVEO, and WilmerHale LLP is serving as AVEO’s legal counsel.

Corporate presentation

On January 6, 2023 Aura Biosciences presented its corporate presentation (Presentation, Aura Biosciences, JAN 6, 2023, View Source [SID1234625958]).

1stOncology is recognized as a
Top 10 Global Pharma Analytic Provider

Continue your journey with 1stOncology by accessing our Free Leading Cancer Conference Whitepapers, signing up for our Free Weekly Newsletter and requesting a Free Demo to see how we can help you be 1st in Oncology!

Year: 2023

First-in-class small molecule antifibrotic and anticancer agents

EVERSANA to Present at the 41st Annual J.P. Morgan Healthcare Conference

bluebird bio Sells Second Priority Review Voucher for $95 Million

AVEO Oncology Stockholders Approve Acquisition by LG Chem

Corporate presentation